Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00246415 · ClinicalTrials.gov registry record · Phase 2

A Placebo-Controlled Trial of Memantine for Alcohol Dependence

A Phase 2 study of Alcohol Abuse and Alcohol Dependence (Primary Condition), sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Completed
Registry status
Phase 2
Development phase
90
Enrollment target
1
Study location

NCT00246415 is a Phase 2 study of Alcohol Abuse and Alcohol Dependence (Primary Condition) that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 90 participants, below the 711-participant average among 46 other Alcohol Abuse trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00246415, a Phase 2 study of Alcohol Abuse and Alcohol Dependence (Primary Condition), has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).

COMPLETED
Registry status
Phase 2
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to obtain a preliminary indication of the safety and effectiveness of oral memantine (40 mg/day) in alcohol dependent patients. This study is a 16-week study comparison of memantine and placebo in patients with alcohol dependence.

Interventions

  • DRUG Memantine

Study Locations (1)

New York

  • New York State Psychiatric Institute - New York

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2002-11
Est. Completion 2005-12
Phase Phase 2

What the Registry Record Tells You About NCT00246415

The ClinicalTrials.gov registry entry for NCT00246415 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 711-participant average among 46 other Alcohol Abuse trials with a reported enrollment target (87% lower). The listed sponsor is National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Alcohol Abuse appearing as the primary indexed condition, and to 1 intervention - of which Memantine is the first listed.

NCT00246415 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00246415 about?

NCT00246415 is a clinical study titled "A Placebo-Controlled Trial of Memantine for Alcohol Dependence". The purpose of this study is to obtain a preliminary indication of the safety and effectiveness of oral memantine (40 mg/day) in alcohol dependent patients. This study is a 16-week study comparison of memantine and placebo in patients with alcohol dependence.

What is the current status of trial NCT00246415?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2002-11. Estimated completion is 2005-12.

What conditions does trial NCT00246415 study?

This clinical trial studies the following conditions: Alcohol Abuse, Alcohol Dependence (Primary Condition).

What interventions are being tested in trial NCT00246415?

The interventions under investigation include: Memantine (DRUG).

Who is sponsoring clinical trial NCT00246415?

This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00246415 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Abuse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.